Vargas-Hernández VM, Ventura-Quintana V, Tovar RJM

Idioma: Español
Referencias bibliográficas: 39
Paginas: 138-148
Archivo PDF: 459.45 Kb.

RESUMEN

Objetivo: Determinar el daño gonadal de las pacientes con cáncer de mama sometidas a quimioterapia.
Material y Método: Estudio observacional prospectivo y comparativo de pacientes con antecedente de cáncer de mama que recibieron quimioterapia (grupo 1), quimioterapia y radioterapia (grupo 2), independientemente de tratamiento quirúrgico y 4 pacientes sin cáncer, grupo control (grupo 3), se determinaron las concentraciones de hormona folículo estimulante, cuenta folicular antral y volumen ovárico con ultrasonido doppler color.
Resultados: Se incluyeron 14 pacientes en diferentes estadios clínicos de cáncer de mama. Encontramos que la quimioterapia y radioterapia disminuyeron la cuenta folicular, principalmente cuando se administran ambos; con daño significativo en los grupos 1 y 2; las concentraciones de hormona folículo estimulante aumentaron en los grupos 1 y 2 con respecto al grupo control, sin diferencias en las pruebas y los diferentes esquemas de quimioterapia, todos provocaron daño ovárico y disfunción ovárica.
Conclusión: Se observó disminucion significativa de la reserva ovárica en las pacientes sometidas a quimioterapia sola o con radioterapia evaluada a través de las concentraciones de FSH basal, conteo folicular y volumen ovárico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, et al. Breast Impact incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Res Treat 2012;134(1):363-70.

2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30.

3. Rodriguez, S., Campo-Engelstein, L., & Emanuel, L. Fertile future? Potential social implications of oncofertility. J Clin Oncol 2013;31(6):665-667.

4. Clarisa R. Gracia and Jacqueline S. Jeruss. Lives in the balance: Women with cancer and the right to fertility care. J Clin Oncol 2013:20;31(6):668-669.

5. Salama M, Mallmann P. Emergency fertility preservation for female patients with impact: clinical perspectives. Anticancer Res 2015;35(6):3117-3127.

6. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 2012;71:28-33.

7. Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny 2017;16(2):47-50.

8. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016;12(20):2333-2344.

9. Spressão M, Oliani AH, Oliani D. Value of the ultrasound in the Study of Ovarian Reserve for Prediction of Oocyte Recovery. Rev Bras Ginecol Obstet 2016;38:499-505.

10. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.

11. Vargas Hernández VM, Vargas Aguilar VM, Tovar Rodriguez JM Cáncer de mama en mujeres adolescentes y en edad reproductiva en Vargas- Hernández VM. 1ª. ed. Cáncer en la Mujer, Edit. Alfil México, 2011:1777-1783.

12. Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, et al. Ovarian function after chemotherapy in 20 impact breast survivors. Curr Oncol 2017;24(6):e494- e502.

13. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast impact: a systematic review and meta-analysis JAMA Oncol 2016;2(1):65-73.

14. Johnson JA, Tough S. Society of Obstetricians and Gynaecologists of Canada. Delayed child-bearing. J Obstet Gynaecol Can 2012;34(1):80-93.

15. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Prevention of chemotherapy-induced ovarian damage. Fertil Steril 2016;105(1):20-9.

16. Balachandren N, Davies M. Fertility, ovarian reserve and cancer Maturitas 2017;105:64-68.

17. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016;14:1.

18. Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation– ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Hum Reprod 2017;32(9):1802-1811.

19. Ahmed S, Sherif Sh, Tamer A, Hesham A and Odette W. Antral 21mpacto f count is a better indicator for the assessment of ovarian reserve. Evidence Based Women’s Health J 2012;2:126-132.

20. Anderson RA, Cameron DA. Pretreatment serum antimüllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast impact. J Clin Endocrinol Metab 2011;96(5):1336-43.

21. de Fine Licht S, Rugbjerg K, Gudmundsdottir T, Bonnesen TG, Asdahl PH, Holmqvist AS, et al. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood impact survivors. PloS Med 2017;14(5):e1002296.

22. Demeestere I, Brice P, Peccatori FA, et al. Gonadotropinreleasing hormone agonist for the prevention of chemotherapy- induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-909.

23. Gerber B, Ortmann O: Prevention of Early Menopause Study (POEMS): Is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa). Arch Gynecol Obstet 2014;290:1051-1053.

24. Ganesh S, Lye MS, Lau FN. Quality of life among breast cancer patients In Malaysia Asian. Pac J Cancer Prev 2016;17(4):1677-1684.

25. Hamish W, Wallace B. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011;117(10 suppl):230;1-10.

26. Kishk EA, Mohammed Ali MH. Effect of a gonadotropinreleasing hormone analogue on cyclophosphamideinduced ovarian toxicity in adult mice. Arch Gynecol Obstet 2013;287(5):1023-9.

27. Welsh LC, Taylor A. Impact of pelvic radiotherapy on the female genital tract and fertility preservation measures. World J Obstet Gynecol 2014;3(2):45-53.

28. Ghadjar P, Budach V, Köhler C, Jantke A, Marnitz S. Modern radiation therapy and potential fertility preservation strategies in patients with cervical impact undergoing chemoradiation. Radiot Oncol 2015;10:50.

29. Mazeron R, Maroun P, Cao K, Mbagui R, Slocker-Escarpa A, Chargari C, Haie-Meder C. Impact of radiotherapy on female fertility. Bull Cancer 2015;102(5):470.

30. Letourneau JM, Smith JF, Ebbel EE, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer 2012;118(18):4579-4588.

31. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-11.

32. Green DM, Sklar CA, Boice JD, Jr., Mulvihill JJ, Whitton JA, Stovall M et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-81.

33. Venturella R, Lico D, Sarica A, Falbo MP, Gulletta E, Morelli M, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters J Ovarian Res 2015;8:21.

34. Bozza C, Puglisi F, Lambertini M, EO, Manno M, Del Mastro L. Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients Endocrine-Related Cancer 2014;21:R51-R65.

35. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction. Acta Obstet Gynecol Scand 2015;94(10):1056-63.

36. Jirge PR. Ovarian reserve tests. J Hum Reprod Sci 2011;4(3):108-113.

37. Kim H, SK, JR, KJ, Suh CS, SH. Fertility preservation for patients with breast cancer: The Korean Society for Fertility Preservation clinical guidelines. Clin Exp Reprod Med 2017;44(4):181-186.

38. Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K. Sphingosine-1- phosphate prevents chemotherapyinduced human primordial follicle death. Hum. Reprod 2014;29(1):107-113.

39. Roness H, Kashi O, Meirow D. Prevention of chemotherapyinduced ovarian damage. Fertil Steril 2016;105(1):20-29.